Personalis Inc (PSNL) - Net Assets
Based on the latest financial reports, Personalis Inc (PSNL) has net assets worth $254.76 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($325.39 Million) and total liabilities ($70.63 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PSNL tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $254.76 Million |
| % of Total Assets | 78.29% |
| Annual Growth Rate | N/A |
| 5-Year Change | -15.83% |
| 10-Year Change | N/A |
| Growth Volatility | 46.22 |
Personalis Inc - Net Assets Trend (2017–2025)
This chart illustrates how Personalis Inc's net assets have evolved over time, based on quarterly financial data. See Personalis Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Personalis Inc (2017–2025)
The table below shows the annual net assets of Personalis Inc from 2017 to 2025. For live valuation and market cap data, see PSNL stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $261.19 Million | +28.69% |
| 2024-12-31 | $202.96 Million | +56.79% |
| 2023-12-31 | $129.44 Million | -40.66% |
| 2022-12-31 | $218.14 Million | -29.70% |
| 2021-12-31 | $310.30 Million | +59.17% |
| 2020-12-31 | $194.94 Million | +82.72% |
| 2019-12-31 | $106.69 Million | +200.28% |
| 2018-12-31 | $-106.39 Million | -14.89% |
| 2017-12-31 | $-92.60 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Personalis Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 53564100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $10.00K | 0.00% |
| Other Comprehensive Income | $104.00K | 0.04% |
| Other Components | $892.33 Million | 341.65% |
| Total Equity | $261.19 Million | 100.00% |
Personalis Inc Competitors by Market Cap
The table below lists competitors of Personalis Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lao Feng Xiang Co Ltd B
SHG:900905
|
$626.26 Million |
|
Propert & Buil
TA:PTBL
|
$626.50 Million |
|
Castle Biosciences Inc
NASDAQ:CSTL
|
$626.62 Million |
|
COFCO Joycome Foods Limited
F:0M7
|
$626.75 Million |
|
Esr Kendall Square Reit Co Ltd
KO:365550
|
$626.23 Million |
|
Beibu Gulf Tourism Corp Ltd
SHG:603869
|
$626.16 Million |
|
Bohai Ferry Co Ltd
SHG:603167
|
$626.09 Million |
|
Carlton Investments Ltd
AU:CIN
|
$625.88 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Personalis Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 202,957,000 to 261,185,000, a change of 58,228,000 (28.7%).
- Net loss of 81,270,000 reduced equity.
- New share issuances of 126,797,000 increased equity.
- Other comprehensive income increased equity by 127,000.
- Other factors increased equity by 12,574,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-81.27 Million | -31.12% |
| Share Issuances | $126.80 Million | +48.55% |
| Other Comprehensive Income | $127.00K | +0.05% |
| Other Changes | $12.57 Million | +4.81% |
| Total Change | $- | 28.69% |
Book Value vs Market Value Analysis
This analysis compares Personalis Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.35x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-4.26 | $9.79 | x |
| 2018-12-31 | $-4.89 | $9.79 | x |
| 2019-12-31 | $5.92 | $9.79 | x |
| 2020-12-31 | $5.67 | $9.79 | x |
| 2021-12-31 | $7.07 | $9.79 | x |
| 2022-12-31 | $4.77 | $9.79 | x |
| 2023-12-31 | $2.69 | $9.79 | x |
| 2024-12-31 | $3.43 | $9.79 | x |
| 2025-12-31 | $2.93 | $9.79 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Personalis Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -31.12%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -116.69%
- • Asset Turnover: 0.21x
- • Equity Multiplier: 1.28x
- Recent ROE (-31.12%) is below the historical average (-30.28%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | -251.23% | 0.28x | 0.00x | $-14.34 Million |
| 2018 | 0.00% | -52.64% | 0.91x | 0.00x | $-9.25 Million |
| 2019 | -23.51% | -38.47% | 0.41x | 1.47x | $-35.75 Million |
| 2020 | -21.18% | -52.49% | 0.32x | 1.26x | $-60.77 Million |
| 2021 | -21.02% | -76.29% | 0.22x | 1.28x | $-96.26 Million |
| 2022 | -51.95% | -174.20% | 0.22x | 1.34x | $-135.13 Million |
| 2023 | -83.66% | -147.38% | 0.33x | 1.74x | $-121.24 Million |
| 2024 | -40.05% | -96.06% | 0.31x | 1.33x | $-101.58 Million |
| 2025 | -31.12% | -116.69% | 0.21x | 1.28x | $-107.39 Million |
Industry Comparison
This section compares Personalis Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $479,332,960
- Average return on equity (ROE) among peers: -102.28%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Personalis Inc (PSNL) | $254.76 Million | 0.00% | 0.28x | $626.23 Million |
| Agilent Technologies Inc (A) | $4.87 Billion | 14.75% | 0.98x | $36.96 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $1.66 Million | -167.28% | 1.68x | $6.13 Million |
| Applied DNA Sciences Inc (APDN) | $8.97 Million | -77.97% | 0.43x | $3.99 Million |
| Biodesix Inc (BDSX) | $20.61 Million | -317.61% | 3.51x | $79.44 Million |
| bioAffinity Technologies, Inc. (BIAF) | $4.86 Million | -163.47% | 0.69x | $6.16 Million |
| Biocept Inc. (BIOCQ) | $37.48 Million | -7.53% | 0.61x | $525.00 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $30.47 Million | -271.32% | 5.29x | $4.31 Billion |
| Burning Rock Biotech Ltd (BNR) | $-603.46 Million | 0.00% | 0.00x | $77.21 Million |
| CareDx Inc (CDNA) | $378.43 Million | 13.89% | 0.30x | $1.13 Billion |
| Check Cap Ltd (CHEK) | $41.31 Million | -46.25% | 0.10x | $9.42 Million |
About Personalis Inc
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole tran… Read more